Puzo Michael J Takes $8.62 Million Position in Danaher Corporation $DHR

Puzo Michael J purchased a new position in Danaher Corporation (NYSE:DHRFree Report) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,274 shares of the conglomerate’s stock, valued at approximately $8,624,000. Danaher makes up about 2.2% of Puzo Michael J’s holdings, making the stock its 19th biggest position.

A number of other large investors also recently modified their holdings of DHR. Edmond DE Rothschild Holding S.A. purchased a new position in Danaher during the second quarter valued at approximately $304,000. Geneva Partners LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $945,000. CM Wealth Advisors LLC purchased a new stake in Danaher in the 2nd quarter worth approximately $431,000. Madison Asset Management LLC bought a new position in Danaher in the 2nd quarter valued at $85,451,000. Finally, Csenge Advisory Group purchased a new position in shares of Danaher during the 2nd quarter valued at $441,000. 79.05% of the stock is currently owned by institutional investors.

Danaher Stock Performance

Danaher stock opened at $211.92 on Thursday. Danaher Corporation has a fifty-two week low of $160.93 and a fifty-two week high of $242.80. The company has a debt-to-equity ratio of 0.48, a quick ratio of 1.25 and a current ratio of 1.65. The stock has a market cap of $148.98 billion, a P/E ratio of 37.64, a price-to-earnings-growth ratio of 2.49 and a beta of 0.78. The firm’s fifty day moving average price is $194.30 and its 200-day moving average price is $192.44.

Danaher (NYSE:DHRGet Free Report) last announced its earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analyst estimates of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The firm’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the previous year, the business earned $0.77 earnings per share. On average, equities research analysts expect that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently weighed in on DHR. Wall Street Zen cut shares of Danaher from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. TD Cowen dropped their price objective on Danaher from $240.00 to $236.00 and set a “buy” rating for the company in a research note on Wednesday, July 22nd. Argus decreased their target price on Danaher from $265.00 to $230.00 and set a “buy” rating on the stock in a research note on Friday, April 24th. Wolfe Research cut Danaher from an “outperform” rating to a “peer perform” rating in a report on Monday, June 1st. Finally, HSBC dropped their price target on Danaher from $270.00 to $230.00 and set a “buy” rating for the company in a research report on Wednesday, June 3rd. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $228.91.

Read Our Latest Report on DHR

About Danaher

(Free Report)

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.

Featured Stories

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHRFree Report).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.